As proof, subcutaneous injection of the PCSK9 inhibitor SBC-115076 had greater benefit than the cholesterol-reducing drug atorvastatin in improving metabolic disorders of obese rats, because, according to the authors, it could decrease PCSK9 activity in the intestine and cholesterol absorption. This evidence concerns the gene PCSK9 and metabolic disease.